Bio­gen push­es in a fresh stack of chips and starts prep­ping a glob­al R&D game plan af­ter watch­ing the cards turn on ear­ly throm­bolyt­ic da­ta

Af­ter pa­tient­ly steer­ing through a decade-long jour­ney for its ear­ly-stage clin­i­cal work, a small Tokyo biotech has clinched a deal to out-li­cense its lead throm­bolyt­ic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER